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Summary.-Adenosine deaminase (ADA) and purine nucleoside phosphorylase
(PNP) levels of peripheral blood mononuclear cells were measured in 34 patients
with various types of solid tumours. The mean ADA activity was found to be
significantly lower than in controls (P <0.005). Patients with nonresectable tumour or
with recurrence after radical surgery showed low ADA levels, while patients
operated upon and without recurrence had enzymatic activity not different from that
of normal controls. The mean value of PNP activity was similar to that of normal
controls; no differences were observed between operated patients without recurrence
and cases with nonresectable tumour or with recurrence after surgical treatment.
No effects on ADA and PNP levels appeared to be induced by chemotherapy.
ADENOSINE D)EAMINASE (EC 3.5.4.4.,
ADA) and purine nucleoside phosphory-
lase (EC 2.4.2.1., PNP) are two enzymes
involved in the purine salvage pathway.
ADA and PNP activities are present in
normal lymphocytes and appear to be
necessary for aneffectiveimmuneresponse.
The first report ofimpaired immunological
function associated with ADA deficiency
was by Giblett et al. (1972) in a patient
with severe combined immunodeficiency.
This finding, which has been substantiated
by other groups (Meuwissen et al., 1975;
Parkman et al., 1975), has stimulated great
interest, because it was the first descrip-
tion of an enzymatic defect linked to a
disorder of specific immunity. Subse-
quently, PNP was shown to be deficient
in some patients with severe T-cell
deficiency and apparently normal humoral
immunity (Giblett et al., 1975; Stoop et al.,
1977; Gelfand et al., 1978; Sandman et al.,
1977; Chen et al., 1979). The biochemical
events which result in immune malfunc-
tion are unclear, but inherited disorders of
purine degradation may impair the im-
mune response.
Lymphocyte ADA activity has been
investigated in acquired diseases also and
a possible relationship between its levels
and immunological changes has been
suggested. Increased ADA activity was
found in typhoid fever and brucellosis
(Galanti et al., 1981), in patients rejecting
transplanted kidneys (Lum et al., 1978),
in acute leukaemia (Smyth & Harrap,
1975) and in some patients with lymphoma
(Meier et al., 1976). In contrast, low ADA
levels were reported in chronic lympho-
cytic leukaemia (Tung et al., 1976) and in
liver cirrhosis (Galanti et al., 1978).
PATIENTS AND METHODS
Patients and controls. 34 patients with
different tumours were studied. The age
range wNas 20-61 years; 89% were male.
Diagnosis was confirmed histologically in 32
cases, while in the remaining 2 the diagnosis
was l)ased on evidence of metastasis and on
the clinical follow-up findings. The patients
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were categorized as follows: (a) Eighteen cases
with tumour actually present at the time of
the study; they include: 14 patients with
nonresectable tumour (4 lung cancer, 4
hepatocarcinomas, 2 gastric cancers, 2 un-
identified tumours with metastasis, 1 Ewing
sarcoma, 1 cancer of the uterus at stage 3).
They did not undergo surgery because of the
advanced stage of their disease (local exten-
sion or metastatic dissemination). Only two
cases were receiving cytostatic treatment,
namely the case of Ewing sarcoma (alternate
courses of vincristine+adriamycin and vin-
cristine +cyclophosphamide) and that of
gastric cancer (methyl-cloroethyl-cyclohexyl-
nitrosourea (Me CCNU) +vincristine +5-
fluorouracil); 4 patients (3 with melanoma,
1 with lung cancer) treated with radical sur-
gery 2-6 years previously, who at varying
times since their operation had developed
recurrence. All ofthem were receiving chemo-
therapy at the time of the study: courses of
5 (3-dimethyl-triazeno)-imidazole-4 carboxa-
mide (DTIC) for melanoma cases and courses
of cyclophospliamide +vincristine +adria-
mycini for lung cancer.
(b) Sixteen patients with previous radical
surgery and without subsequent recurrence
(6 melanomas, 1 lung cancer, 3 glioblastomas,
1 glioma, 2 kidney adenocarcinomas, 2 hypo-
physeal adenocarcinomas, 1 oesophageal
cancer). The operation, 3-15 months before
the study, had totally removed the neoplastic
tissue and there was no evidence ofmetastasis
or recurrence at the time of the study. In all
cases but two (1 glioblastoma and 1 oeso-
phageal cancer) surgery was followed by
courses of chemotherapy. Melanoma cases
were on DTIC; the lung cancer case was
receiving cyclophosphamide +vincristine +
adriamycin; patients with glioblastoma and
with glioma were receiving bis-cloroethyl-
nitrosourea (CENU) +vincristine +procarba-
zine; hypophyseal adenocarcinoma cases were
receiving BCNU; one of the patients with
adenocarcinoma of the kidney was on treat-
ment with vincristine +cyclophosphamide,
and the other with vincristine +adriamycin.
Eighteen healthy subjects, chiefly males,
aged 20-50 years, were used as controls.
Lymphocyte separation.-Mononuclear cells
(lymphocytes and monocytes) were isolated
by the method of Boyum (1968). Heparinized
peripheral blood was diluted 1:1 with Hanks'
solution (pH 7.5) and layered on to a Ficoll-
paque gradient. After centrifugation at 400 g
for 30 min, the lymphocyte halo was removed
by aspiration and washed twice in Hanks'
solution. The lymphocyte suspensions, con-
taining 2-5 x 106 cells per ml, with contamina-
tion by erythrocytes and granulocytes of less
than 500, were sonicated for 45 sec at 25 kc/
sec (cell disruption was ascertained micro-
scopically). The lymphocyte extracts were
centrifuged at 800 g for 10 min and the super-
natants were immediately used for analysis.
ADA and PNP determination.-ADA acti-
vity was measured by a colorimetric mehod
(Giusti, 1974) based on the determination of
the amount of NH3 released in the reaction
mixture, wrhich contained 1 ml of 20mM
adenosine in 50mM phosphate buffer at pH
7-2 and 100 ,ul oflymphocyte extract. Control
tubes were prepared by omitting the substrate
or the enzyme source. After 60min incubation
at 37°C, NH3 was assayed by Chaney and
Marbach's reagents (Chaney & Marbach,
1962) and the optical density was measured
at 628 nm. The enzymeactivity was calculated
bvreferring to a standard curve ofammonium
sulphate in buffer. PNPactivity was measured
in a final volume of 1 035 ml containing 1 ml
of 5mM inosine in 50mM phosphate buffer at
pH 7 5, 25 ,ul oflymphocyte extract and 10 ,ul
of xanthine oxidase (10 mg/ml, 04 u/mg,
Boehringer-Mannhein). The reaction, carried
out at 37°C, was followed spectrophoto-
metrically at 293 nm. ADA and PNP activi-
ties were expressed as nmol of adenosine and
inosine respectively converted per mg of
protein. Protein was determined by the
method of Lowry et al. (1951), with bovine
serum albumin as standard.
Statistical analysis -Results were expres-
sed as mean + s.d. and compared by Student's
t test.
RESULTS
Individual values for lymphocyte ADA
activity of normal controls and tumour
patients are represented in the Figure.
Mean ADA and PNP values of normal
controls and of different groups of tumour
patients are reported in Table I, which
shows that the mean ADA activity of 34
tumour patients is significantly lower
(P < 0.005) than that of normal controls.
When we consider the 18 patients with
nonresectable tumours, or with recurrence
after surgery, we observe that their mean
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FIGURE.-Lymphocyte adenosine deaminase
levels in: (0) normal controls; (A) tumour
patients with recurrence after surgery;
(C1) patients with nonresectable tumour;
(0) patients operated on and without re-
currence.
ADA value is lower than the control mean
(P< 0.001). In contrast, the 16 tumour
* patients previously operated and without
recurrence showed a mean ADA value no
different from that of controls.
* Data concerning lymphocyte PNP acti-
vity and reported in Table I show that the
mean value for tumour patients does not
differ from that of the controls; no sig-
* nificant differences were found even when
our patients were considered in relation
* to previous surgery or to recurrence after
surgery.
To evaluate a possible action of chemo-
* therapy on lymphocyte enzyme levels, we
* have allocated tumour patients according
to cytostatic treatment (Table II).
. b We can see that of 16 patients pre-
viously operated and without subsequent
recurrence, 14 are on chemotherapy; their
mean ADA activity is not different from
that ofcontrols. Furthermore, in the group
of patients with nonresectable cancer or
with recurrence after surgery, no difference
in ADA activity was found between the
mean value of the 6 cases on chemo-
therapy (16.49 + 5.84) and that of the 12
untreated cases (15-03 + 4-16). PNP acti-
vity also appears to be unaffected by
chemotherapy; the 14 operated patients
without recurrence and on chemotherapy
do not significantly differ from controls.
Moreover, in the group of patients with
nonresectable tumour or with recurrence
after surgery, the cases on chemotherapy
TABLE I.-Lymphocyte adenosine deaminase (ADA) and purine nucleoside phosphorylase
(PNP) activities in normal controls and tumour patients
ADA activity PNP activity
(nmol/min/mg (nmol/min/mg
protein) protein)
No. Mean+s.d. P* Mean+s.d. P*
Normal controls 18 28-41 + 3 93 - 92-92+15-50
Tumour patients
Total 34 21-41+8-50
Patients with nonresectable
tumour orrecurrence
after surgery 18 15-52 + 4-66
Patients operated and
without recurrence 16 28-03 + 6-77
* Significance levels in comparison with controls.
<0-005 99-20+ 32-30 N.S.
< 0 001 94-53 + 25-34
N.S. 104-46+ 38-89
N.S.
N.S.
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TABLE II.-Lymphocyte adenosine deaminase (ADA) andpurine nucleoside phosphorylase
(PNP) levels in tumour patients according to chemotherapy
ADA activity PNP activity
(nmol/min/mg (nmol/min/mg
protein) protein)
No. Mean + s.d. P* Mean+s.d. P*
Normal controls 18 28-41 + 3.93 92-92+15-50
Patients operated and
without recurrence, on
chemotherapy 14 28-31 + 6-72 N.S. 108-09 + 40 07 N.S.
Patients with nonresectable
tumour or with recurrence
after surgery
On chemotherapy 6 16-49+ 5-84 < 0-001 102-93 + 27-45 N.S.
Without chemotherapy 12 15-03 + 4-16 < 0-001 90-32 + 24-34 N.S.
* Significance levels in comparison with normal controls.
show a mean PNP value (102.93 + 27.45)
not significantly different from that of
cases without chemotherapy (90f32 +
24.34).
DISCUSSION
The relationship between abnormalities
ofpurine catabolism and immune function
found in inherited immune-deficiency dis-
eases has stimulated investigations on
levels of ADA and PNP activities in
peripheral lymphocytes from patients
with acquired diseases. Data concerning
cancer patients are still scanty, but a low
mean value of ADA activity is proven in
patients with solid tumours (Uberti et al.,
1976; Ogawa et al., 1978).
In the present study we have measured
ADA and PNP levels in peripheral
lymphocytes from 34 patients with various
solid tumours. For ADA activity, our
results confirm a significant reduction in
tumour patients. Our data also suggest
that ADA levels are related to cancer
progression, i.e., low levels are found in
patients with advanced tumour; in our
series, in fact, 89% of patients with
advanced tumour showed individual ADA
values below the control range. The 16
cases without recurrence after surgical
removal of the primary tumour had a
mean ADA value similar to that of
controls, while 3/4patients with recurrence
after surgery showed single ADA values
lower than the control range.
15
Whether decreased lymphocyte ADA
levels are related to the presence of
neoplastic tissue, and whether normal
ADA levels could be restored by radical
tumour removal, need to be studied. We
have no preoperative data on lymphocyte
ADA levels from our patients undergoing
surgery and in the literature there are no
data on when an ADA decrease might
occur after surgical removal of a tumour.
Finally, lymphocyte ADA activity ap-
pears to be unaffected by chemotherapy.
In our series the patients surgically
treated, without recurrence, andon chemo-
therapy, showed control levels of ADA
and patients with advanced cancer,
whether on chemotherapy or not, showed
low ADA levels.
As far as lymphocyte PNP activity is
concerned, our control values range from
72-02 to 125-10 nmol/min/mg protein and
are similar to those found by others
(Ogawa et a ., 1978; Sidi et al., 1979; Mejer
& Nygaard, 1979). Lymphocyte PNP
levels of tumour patients do not differ
from the controls, even when they are
considered in relation to previous surgery,
to degree of neoplastic growth and to
chemotherapy.
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